(Difference between pages)

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

Content deleted Content addedVisualWikitext

Revision as of 10:04, 5 December 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,074 edits Saving copy of the {{drugbox}} taken from revid 462991224 of page Erlotinib for the Chem/Drugbox validation project (updated: 'DrugBank').		Latest revision as of 16:56, 12 January 2025 edit Arthurfragoso (talk | contribs)Extended confirmed users, Template editors4,591 edits dark mode fix
Line 1:		Line 1:
			{{Short description|Medication for treatment of non-small-cell lung cancer}}
	{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
			{{Use dmy dates|date=March 2024}}
	{{Drugbox
			{{cs1 config|name-list-style=vanc|display-authors=6}}
	| Verifiedfields = changed
			{{Infobox drug
	| verifiedrevid = 459451414
			| verifiedrevid = 464189825
	| IUPAC_name = ''N''-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)<br>quinazolin-4-amine
	| image = Erlotinib Structural Formulae.png		| image = Erlotinib.svg
			| image_class = skin-invert-image
	| width = 250		| width = 250
			| alt =
	| image2 = Erlotinib-1m17-3D-balls.png		| image2 = Erlotinib-1m17-3D-balls.png
			| alt2 =
	<!--Clinical data-->		<!-- Clinical data -->
	| tradename = Tarceva		| tradename = Tarceva
	| Drugs.com = {{drugs.com|monograph|erlotinib}}		| Drugs.com = {{drugs.com|monograph|erlotinib}}
	| MedlinePlus = a605008		| MedlinePlus = a605008
	| licence_EU = Tarceva		| DailyMedID = Erlotinib
			| pregnancy_AU = C
	| licence_US = Erlotinib
			| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Erlotinib (Tarceva) Use During Pregnancy | website=Drugs.com | date=1 November 2019 | url=https://www.drugs.com/pregnancy/erlotinib.html | access-date=23 December 2019 | archive-date=12 November 2019 | archive-url=https://web.archive.org/web/20191112154642/https://www.drugs.com/pregnancy/erlotinib.html | url-status=live }}</ref><ref name="Tarceva PI" />
	| pregnancy_US = D
			| routes_of_administration = ]
			| ATC_prefix = L01
			| ATC_suffix = EB02
			| legal_AU = S4
			| legal_AU_comment = <ref name="Tarceva PI">{{cite web | title = Tarceva (Erlotinib hydrochloride) | publisher = Australian Product Information | url = https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=roptarce10415 | work = Roche Products Pty Limited | date = 31 August 2022 }}</ref>
	| legal_UK = POM		| legal_UK = POM
	| legal_US = Rx-only		| legal_US = Rx-only
			| legal_US_comment = <ref name="Tarceva label" />
	| routes_of_administration = Oral ]s
	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->
	| bioavailability = 59%		| bioavailability = 59%
	| protein_bound = 95%		| protein_bound = 95%
	| metabolism = ] (mainly ], less ])		| metabolism = ] (mainly ], less ])
	| elimination_half-life = 36.2 hrs (])		| elimination_half-life = 36.2 hrs (])
	| excretion = >98% as metabolites, of which >90% via ], 9% via ]		| excretion = >98% as metabolites, of which >90% via ], 9% via ]
	<!--Identifiers-->		<!--Identifiers-->
			| IUPHAR_ligand = 4920
	| CASNo_Ref = {{cascite|correct|CAS}}
	| CAS_number_Ref = {{cascite|correct|??}}		| CAS_number_Ref = {{cascite|correct|??}}
	| CAS_number = 183321-74-6		| CAS_number = 183321-74-6
	| ATC_prefix = L01
	| ATC_suffix = XE03
	| PubChem = 176870		| PubChem = 176870
	| DrugBank_Ref = {{drugbankcite|changed|drugbank}}		| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
	| DrugBank = DB00530		| DrugBank = DB00530
	| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}		| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
Line 45:		Line 52:
	| ChEMBL_Ref = {{ebicite|correct|EBI}}		| ChEMBL_Ref = {{ebicite|correct|EBI}}
	| ChEMBL = 553		| ChEMBL = 553
			| synonyms = Erlotinib hydrochloride
	<!--Chemical data-->		<!--Chemical data-->
			| IUPAC_name = {{plainlist|
	| C=22 | H=23 | N=3 | O=4
			*''N''-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)
	| molecular_weight = 393.436 g/mol
			*quinazolin-4-amine
			}}
			| C=22 | H=23 | N=3 | O=4
	| smiles = COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C		| smiles = COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C
	| InChI = 1/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
	| InChIKey = AAKJLRGGTJKAMG-UHFFFAOYAM
	| StdInChI_Ref = {{stdinchicite|correct|chemspider}}		| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChI = 1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)		| StdInChI = 1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
Line 57:		Line 66:
	| StdInChIKey = AAKJLRGGTJKAMG-UHFFFAOYSA-N		| StdInChIKey = AAKJLRGGTJKAMG-UHFFFAOYSA-N
	}}		}}
			<!-- Definition and medical use -->
			'''Erlotinib''', sold under the brand name '''Tarceva''' among others, is a ] used to treat ] (NSCLC) and ].<ref name=AHFS2019/> Specifically it is used for NSCLC with mutations in the ] (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has ].<ref name=AHFS2019/> It is taken ].<ref name=AHFS2019/>
			<!-- Side effects and mechanism -->
			Common side effects include rash, diarrhea, muscle pain, joint pain, and cough.<ref name=AHFS2019/><ref name="Tarceva label">{{cite web | title=Tarceva- erlotinib hydrochloride tablet | website=] | date=12 December 2018 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20 | access-date=23 December 2019 | archive-date=6 August 2020 | archive-url=https://web.archive.org/web/20200806135458/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20 | url-status=live }}</ref> Serious side effects may include lung problems, ], ], ], ], and ].<ref name=AHFS2019/> Use in ] may harm the baby.<ref name=AHFS2019/> It is a receptor ], which acts on the ] (EGFR).<ref name=AHFS2019/>
			<!-- History and culture -->
			Erlotinib was approved for medical use in the United States in 2004.<ref>{{cite web | title=Drug Approval Package: Tarceva (Erlotinib) NDA #021743 | website=U.S. ] (FDA) | date=28 March 2005 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm | access-date=23 December 2019 | archive-date=23 December 2019 | archive-url=https://web.archive.org/web/20191223215422/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva.cfm | url-status=live }}</ref><ref name=AHFS2019>{{cite web |title=Erlotinib Monograph for Professionals |url=https://www.drugs.com/monograph/erlotinib.html |website=Drugs.com |access-date=12 November 2019 |archive-date=24 December 2019 |archive-url=https://web.archive.org/web/20191224052912/https://www.drugs.com/monograph/erlotinib.html |url-status=live }}</ref><ref name="Tarceva label" /> It is on the ].<ref name="WHO21st">{{cite book |title=World Health Organization model list of essential medicines: 21st list 2019 |date=2019|hdl=10665/325771 | publisher = World Health Organization |last1=Organization |first1=World Health }}</ref>
			==Medical uses==
			===Lung cancer===
			Erlotinib in unresectable non-small cell lung cancer when added to chemotherapy improves ] by 19%, and improved ] (PFS) by 29%, when compared to chemotherapy alone.<ref>{{Cite web |url=http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756 |title=2009 - SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. |access-date=18 December 2010 |archive-date=22 December 2010 |archive-url=https://web.archive.org/web/20101222034936/http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756 |url-status=dead }}</ref><ref>{{Cite web |url=http://www.tarceva.com/docs/Indication_Announcement_Letter.pdf |title=April 2010 - Tarceva Indication Announcement Letter |access-date=18 December 2010 |archive-date=16 July 2011 |archive-url=https://web.archive.org/web/20110716192656/http://www.tarceva.com/docs/Indication_Announcement_Letter.pdf |url-status=live }}</ref><ref name="Gijtenbeek 00239–2022">{{cite journal | vauthors = Gijtenbeek RG, van der Noort V, Aerts JG, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJ, Timens W, Schuuring E, Janssen JD, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BE, Groen HJ, van Geffen WH, van der Wekken AJ | title = Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) ''versus'' intercalated TKI with chemotherapy for ''EGFR''-mutated nonsmall cell lung cancer | journal = ERJ Open Research | volume = 8 | issue = 4 | pages = 00239–2022 | date = October 2022 | pmid = 36267895 | pmc = 9574558 | doi = 10.1183/23120541.00239-2022 }}</ref> The U.S. ] (FDA) approved erlotinib for the treatment of locally advanced or ] ] that has failed at least one prior ] regimen.<ref>{{cite journal | vauthors = Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R | title = FDA drug approval summary: erlotinib (Tarceva) tablets | journal = The Oncologist | volume = 10 | issue = 7 | pages = 461–466 | date = August 2005 | pmid = 16079312 | doi = 10.1634/theoncologist.10-7-461 | s2cid = 10218263 | doi-access = free }}</ref>
			In lung cancer, erlotinib has been shown to be effective in patients with or without EGFR mutations, but appears to be more effective in patients with EGFR mutations.<ref>{{cite journal | vauthors = Kobayashi K, Hagiwara K | title = Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC) | journal = Targeted Oncology | volume = 8 | issue = 1 | pages = 27–33 | date = March 2013 | pmid = 23361373 | pmc = 3591525 | doi = 10.1007/s11523-013-0258-9 }}</ref><ref name="Qi">{{cite journal | vauthors = Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y | title = Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis | journal = Asian Pacific Journal of Cancer Prevention | volume = 13 | issue = 10 | pages = 5177–5182 | year = 2012 | pmid = 23244131 | doi = 10.7314/APJCP.2012.13.10.5177 | doi-access = free }}</ref> Overall survival, progression-free survival and one-year survival are similar to standard second-line therapy (docetaxel or pemetrexed). Overall response rate is about 50% better than standard second-line chemotherapy.<ref name="Qi"/> Patients who are non-smokers, and light former smokers, with adenocarcinoma or subtypes like BAC are more likely to have EGFR mutations, but mutations can occur in all types of patients. A test for the EGFR mutation has been developed by ].<ref>{{Cite press release|url=https://www.roche.com/investors/updates/inv-update-2010-11-23.htm|title=Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test|website=Roche|access-date=10 January 2020|archive-date=24 February 2022|archive-url=https://web.archive.org/web/20220224044600/https://www.roche.com/investors/updates/inv-update-2010-11-23|url-status=live}}</ref>
			===Pancreatic cancer===
			In November 2005, the FDA approved erlotinib in combination with ] for treatment of locally advanced, unresectable, or metastatic ].<ref>{{citation | vauthors=Takimoto CH, Calvo E | url=http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628 | title=Principles of Oncologic Pharmacotherapy | date=15 April 2009 | access-date=18 June 2009 | archive-date=15 May 2009 | archive-url=https://web.archive.org/web/20090515221337/http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628 | url-status=live }}</ref>
			===Resistance to treatment===
			]
			As with other ATP competitive small molecule tyrosine kinase inhibitors, such as ] in ], patients rapidly develop resistance. In the case of erlotinib this typically occurs 8–12 months from the start of treatment. Over 50% of resistance is caused by a mutation in the ATP binding pocket of the EGFR kinase domain involving substitution of a small polar threonine residue with a large nonpolar methionine residue (]).<ref name="pmid17085664">{{cite journal | vauthors = Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W | title = Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors | journal = Clinical Cancer Research | volume = 12 | issue = 21 | pages = 6494–6501 | date = November 2006 | pmid = 17085664 | doi = 10.1158/1078-0432.CCR-06-1570 | doi-access = free }}</ref>
			Approximately 20% of drug resistance is caused by amplification of the ], which drives ] dependent activation of ].<ref name="pmid17463250">{{cite journal | vauthors = Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA | title = MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | journal = Science | volume = 316 | issue = 5827 | pages = 1039–1043 | date = May 2007 | pmid = 17463250 | doi = 10.1126/science.1141478 | s2cid = 23254145 | bibcode = 2007Sci...316.1039E | doi-access = free }}</ref><ref name="pmid18093943">{{cite journal | vauthors = Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W | title = MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 104 | issue = 52 | pages = 20932–20937 | date = December 2007 | pmid = 18093943 | pmc = 2409244 | doi = 10.1073/pnas.0710370104 | doi-access = free | bibcode = 2007PNAS..10420932B }}</ref>
			==Side effects==
			===Common===
			* ] occurs in the majority of patients. This resembles acne and primarily involves the face and neck. It is self-limited and resolves in the majority of cases, even with continued use. Some clinical studies have indicated a correlation between the severity of the skin reactions and increased survival though this has not been quantitatively assessed.<ref>{{cite journal | vauthors = Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M | title = Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer | journal = Lung Cancer | volume = 51 | issue = 1 | pages = 89–96 | date = January 2006 | pmid = 16290256 | doi = 10.1016/j.lungcan.2005.09.002 }}</ref> The ''Journal of Clinical Oncology'' reported in 2004 that "cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies."<ref>{{cite journal | vauthors = Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P | title = Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | journal = Journal of Clinical Oncology | volume = 22 | issue = 16 | pages = 3238–3247 | date = August 2004 | pmid = 15310767 | doi = 10.1200/JCO.2004.11.057 | doi-access = free }}</ref> The newsletter ''Lung Cancer Frontiers'' reported in its October 2003 issue, "Patients with moderate to severe cutaneous reactions have a far better survival, than those with only mild reactions and much better than those with no cutaneous manifestations of drug effects."<ref>{{cite journal | vauthors = Petty TL | title = Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer | journal = Journal of Clinical Oncology | volume = 1 | issue = 17 | pages = 3–4 | year = 2003 }}</ref>
			* ]
			* Loss of appetite
			* ]<ref name="Gijtenbeek 00239–2022"/>
			* Partial hair loss (by strands, not typically in clumps)
			===Rare===
			* interstitial ], which is characterized by cough and increased ]. This may be severe and must be considered among those patients whose breathing acutely worsens.
			* ], such as eyelashes
			* gastrointestinal tract toxicity
			** serious or fatal ]s
			* skin toxicity
			** bullous, blistering, and exfoliative skin conditions (some fatal)
			** ]/]<ref>{{cite journal | vauthors = Li X, Kamenecka TM, Cameron MD | title = Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile | journal = Drug Metabolism and Disposition | volume = 38 | issue = 7 | pages = 1238–1245 | date = July 2010 | pmid = 20382753 | pmc = 3202369 | doi = 10.1124/dmd.109.030361 }}</ref>
			* ocular disorders
			** corneal lesions
			* Pulmonary toxicity
			** ]
			** ] (BOOP)
			** ]
			** fatal asymmetric ]<ref>{{cite journal | vauthors = Ren S, Li Y, Li W, Zhao Z, Jin C, Zhang D | title = Fatal asymmetric interstitial lung disease after erlotinib for lung cancer | journal = Respiration; International Review of Thoracic Diseases | volume = 84 | issue = 5 | pages = 431–435 | year = 2012 | pmid = 22889962 | doi = 10.1159/000339508 | doi-access = free }}</ref>
			== Interactions ==
			Erlotinib is not a substrate for either of hepatic ]s (OATP1B1 or OATP1B3).<ref name="pmid24643910">{{cite journal | vauthors = Khurana V, Minocha M, Pal D, Mitra AK | title = Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors | journal = Drug Metabolism and Drug Interactions | volume = 29 | issue = 3 | pages = 179–190 | date = March 2014 | pmid = 24643910 | pmc = 4407685 | doi = 10.1515/dmdi-2013-0062 }}</ref> Also, erlotinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.<ref name="Khurana V_2014">{{cite journal | vauthors = Khurana V, Minocha M, Pal D, Mitra AK | title = Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors | journal = Drug Metabolism and Drug Interactions | volume = 29 | issue = 4 | pages = 249–259 | date = May 2014 | pmid = 24807167 | pmc = 4407688 | doi = 10.1515/dmdi-2014-0014 }}</ref>
			Erlotinib is mainly metabolized by the liver enzyme ]. Compounds which induce this enzyme (i.e. stimulate its production), such as ], can lower erlotinib concentrations, while inhibitors can increase concentrations.<ref>{{cite book|title=Austria-Codex|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2010|edition=2010/2011|language=de}}</ref>
			==Mechanism==
			Erlotinib is an epidermal growth factor receptor inhibitor (]). The drug follows Iressa (]), which was the first drug of this type. Erlotinib specifically targets the ] (EGFR) ], which is highly expressed and occasionally ] in various forms of cancer. It binds in a reversible fashion to the ] (ATP) binding site of the receptor.<ref>{{cite journal | vauthors = Raymond E, Faivre S, Armand JP | title = Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy | journal = Drugs | volume = 60 | issue = Suppl 1 | pages = 15–23; discussion 41–2 | year = 2000 | pmid = 11129168 | doi = 10.2165/00003495-200060001-00002 | s2cid = 10555942 | doi-access = free }}</ref> For the signal to be transmitted, two EGFR molecules need to come together to form a ]. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.
			==Society and culture==
			It is marketed in the United States by ]<ref name="Tarceva label" /> and ]<ref>{{cite journal | title = Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415 | journal = Drugs in R&D | volume = 4 | issue = 4 | pages = 243–248 | date = 2003 | pmid = 12848590 | doi = 10.2165/00126839-200304040-00006 | author1 = Adis International Ltd }}</ref> and elsewhere by ].<ref>{{Cite web|url=https://www.genomeweb.com/diagnostics/fda-approves-roche-test-cdx-tarceva-treating-certain-nsclc-patients|title=FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients|website=GenomeWeb|date=15 May 2013|language=en-us|access-date=10 January 2020|archive-date=6 September 2019|archive-url=https://web.archive.org/web/20190906203021/https://www.genomeweb.com/diagnostics/fda-approves-roche-test-cdx-tarceva-treating-certain-nsclc-patients|url-status=live}}</ref>
			The drug's U.S. patent expired in 2020.<ref>{{cite web | title = Erlotinib - Generic Drug Details | url = http://drugpatentwatch.com/p/ingredient/erlotinib | archive-url = https://web.archive.org/web/20160428083918/http://drugpatentwatch.com/p/ingredient/erlotinib | archive-date=28 April 2016 | work = DrugPatentWatch.com }}</ref> In May 2012, the US District Court of Delaware passed an order in favor of OSI Pharmaceutical LLC against Mylan Pharmaceuticals upholding the validity of the patent for Erlotinib.{{citation needed|date=December 2019}} In India, generic pharmaceutical firm ] is battling{{when|date=December 2019}} with Roche against the Indian patent for this drug.<ref>{{cite web | title=Roche and India's Glenmark reach truce over generic Tarceva | website=GaBI Online | date=22 January 2016 | url=http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva | archive-url=https://web.archive.org/web/20191224075230/http://www.gabionline.net/Generics/News/Roche-and-India-s-Glenmark-reach-truce-over-generic-Tarceva | archive-date=24 December 2019 | url-status=live | access-date=23 December 2019}}</ref><ref>{{cite news | title=Cancer drug: Supreme Court allows Cipla to withdraw appeal against Roche | website=The Economic Times | date=16 June 2017 | url=https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms | archive-url=https://web.archive.org/web/20191224075759/https://economictimes.indiatimes.com/cancer-drug-supreme-court-allows-cipla-to-withdraw-appeal-against-roche/articleshow/59176743.cms | archive-date=24 December 2019 | url-status=live | access-date=23 December 2019}}</ref>
			== References ==
			{{reflist}}
			== External links ==
			* {{cite web | title=Erlotinib | website=National Cancer Institute | url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erlotinib-hydrochloride }}
			{{Targeted cancer therapeutic agents}}
			{{Growth factor receptor modulators}}
			{{Portal bar|Medicine}}
			]
			]
			]
			]
			]
			]
			]
			]
			]
			]
			]
			]
			]